A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules

NCT ID: NCT00281606

Last Updated: 2020-06-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 65 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-02-14
• Study Completion Date: 2012-06-13

Brief Summary

Guidelines have continued to list lopinavir/ritonavir as a preferred protease inhibitor-containing regimen for HIV-infected individuals. There has recently been increasing interest in once daily therapy. While lopinavir/ritonavir has recently been approved as a once daily therapy it was associated with considerable diarrhea in those treated with soft gel capsules. It is the hope that alternative formulations of lopinavir/ritonavir may provide similar pharmacokinetics with improved tolerability. This includes the possibility of using liquid or newly released tablets. This study will treat people tolerating their current regimen with up to four weeks of each formulation with several assessments of pharmacokinetics and tolerability for each.

Detailed Description

This study is designed to assess the tolerability of different forms (liquid, capsules or tablets) of lopinavir/ritonavir given once-daily as part of combination therapy for HIV infection. Study subjects will be those tolerating a stable regimen of HIV medications with undetectable levels of HIV in their blood. They will be assigned by chance to receive once daily liquid or soft gel capsules of lopinavir/ritonavir for up to four weeks. At that time they will receive the alternative formulation for up to four weeks. They will then be given once daily lopinavir/ritonavir in the recently released tablet formulation. After up to four weeks of each of these formulations several assessments will be made of the overall tolerability of the drug. After four weeks of tablets they will be allowed to take whatever regimen they want and will be followed for an additional 36 weeks for a total duration of study of up to 48 weeks. The pharmacokinetics of each formulation of lopinavir/ritonavir given once daily will also be assessed in a subset of study subjects.

Conditions

HIV Infection

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

LPV/r (800/200 mg) 10 ml liquid

Once daily Lopinovir/ritonavir (800/200 mg) taken as a 10 ml liquid

Group Type: ACTIVE_COMPARATOR

Different formulations of once-daily lopinavir/ritonavir

Intervention Type: DRUG

CCTG585 is a randomized, open-label, two arm cross-over study to compare the tolerability of once daily LPV/r liquid versus capsules

LPV/r (800/200 mg) 6 gel capsules

Once daily Lopinavir/ritonavir (800/200 mg) as 6 gel capsules

Group Type: ACTIVE_COMPARATOR

Different formulations of once-daily lopinavir/ritonavir

Intervention Type: DRUG

CCTG585 is a randomized, open-label, two arm cross-over study to compare the tolerability of once daily LPV/r liquid versus capsules

Interventions

Different formulations of once-daily lopinavir/ritonavir

CCTG585 is a randomized, open-label, two arm cross-over study to compare the tolerability of once daily LPV/r liquid versus capsules

Intervention Type: DRUG

Other Intervention Names

Lopinavir/Ritonavir (LPV/r)

Eligibility Criteria

Inclusion Criteria

• Ability and willingness of subject or legal guardian/representative to give written informed consent.
• HIV-1 infected.
• At least 18 years of age
• Have the last two HIV-1 RNA measurements performed prior to screening be <50 or 75 copies/mL within the last 180 days, as well as at the time of screening.
• No evidence of primary PI mutations (defined by IAS-USA) documented on previous resistance testing, if ever performed and available, or suggested to be present by previous treatment history.
• Laboratory values:

• Absolute neutrophil count (ANC) >500/mm3.
• -Hemoglobin >7.0 g/dL.

• platelet count >50,000/mm3.
• AST (SGOT), ALT (SGPT), and alkaline phosphatase <5 X ULN.
• Total bilirubin <2.5 x ULN, unless on IDV or ATV in which case must be <1.5 x ULN of direct bilirubin.
• Calculated creatinine clearance >50 mL/min as estimated by the Cockcroft-Gault equation
• For women of reproductive potential, negative serum or urine pregnancy test within 7 days prior to initiating study medications. If participating in sexual activity that could lead to pregnancy, female study subjects must use two forms of contraception, one of which must be a barrier method. All subjects must continue to use contraception for 6 weeks after stopping the study medications.
• Willingness to take an alcohol containing product.
• Karnofsky performance score >70.

Exclusion Criteria

• Pregnancy or breast-feeding
• Greater than Grade 1 diarrhea or nausea (as defined by protocol)
• Use of a NNRTI within 12 weeks of screening
• Use of antimotility or antiemetics during the 14 days prior to screening
• Use of any of the prohibited medications (defined by protocol) within 30 days of study entry.
• Need to continue the use of prohibited or select precautionary medications (defined by protocol)
• Known hypersensitivity to lopinavir/ritonavir
• Active drug or alcohol use or dependence which, in the Investigator's opinion, may interfere with adherence to study requirements or endanger subject's health while on the study
• Serious illness requiring systemic treatment and/or hospitalization until subject either completes therapy or is clinically stable on therapy, in the opinion of the investigator, for at least 30 days prior to study entry.
• Acute therapy for serious infection or other serious medical illnesses (in the judgment of the site investigator) requiring systemic treatment and/or hospitalization within 14 days prior to study entry.
• Use of immunomodulators (e.g., interleukins, interferons, cyclosporine), HIV-1 vaccine, systemic cytotoxic chemotherapy, or investigational therapy within 30 days prior to study entry

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Abbott

INDUSTRY

Sponsor Role: collaborator

University of California, San Diego

OTHER

Sponsor Role: lead

Responsible Party

J Allen McCutchan

Prof Emeritus

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Eric Daar, MD

Role: PRINCIPAL_INVESTIGATOR

University of California, Los Angeles

Locations

UCI

Irvine, California, United States

USC

Los Angeles, California, United States

UCSD

San Diego, California, United States

Santa Clara Valley Medical Center

San Jose, California, United States

Harbor-UCLA Medical Center

Torrance, California, United States

Countries

United States

References

1. Best B, Rieg G, Sun S, Jain S, Kemper C, Diamond C, Hermes A, Haubrich R, Daar E, and California Collaborative Treatment Group (CCTG) 585 Team. Increased lopinavir concentrations on once-daily tablets as compared with capsules and liquid formulations. 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA. Abstract 766a. 2. CDB088 Abstract Switching to once-daily (QD) lopinavir/ritonavir (LPV/r) liquid (Liq), capsules (caps) and tablets (tabs): a randomized, ppen label, cross-over study (CCTG 585). 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town 2009 G. Rieg1, S. Jain2, S. Sun2, R. Larsen3, C. Kemper4, C. Diamond5, S. Schneider6, D. Shamblaw7, A. Hermes8, R. Haubrich9, E. Daar10, California Collaborative Treatment Group (CCTG)

Reference Type: RESULT

Other Identifiers

CCTG 585

Identifier Type: -

Identifier Source: org_study_id